ASCO 2016 highlights for CLL

William Wierda, MD, PhD from the University of Texas MD Anderson Cancer Center, Houston, TX discusses his highlights for chronic lymphocytic leukemia (CLL) from the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL. Prof. Wierda mentions the update on venetoclax in patients who have relapsed or are intolerant to ibrutinib or idelalisib, the idelalisib plus ofatumumab as well as the bendamustine plus rituximab and idelalisib randomized trials.

Share this video  
Similar topics